Cytek Biosciences, Inc. 8-K

What Happened
Cytek Biosciences, Inc. announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025 in a press release dated January 12, 2026. The company furnished that press release as Exhibit 99.1 in a Form 8-K filed on January 13, 2026 under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release date: January 12, 2026; Form 8-K filed: January 13, 2026.
• Subject: preliminary, unaudited revenue for Q4 2025 and fiscal year ended December 31, 2025.
• The press release was furnished as Exhibit 99.1 to the 8-K (the filing does not include audited financial statements).

Why It Matters
This filing gives investors an early, unaudited look at Cytek’s revenue performance for the most recent quarter and full year, which can help assess near‑term business trends ahead of formal audited results and the company’s periodic reports. Because the figures are described as preliminary and unaudited, investors should wait for the company’s full earnings release and audited financial statements for complete, confirmed results.